Polymorphism and patents
A brief introduction to patents is followed by a discussion of the two main issues of patents on (pharmaceutical) polymorphs from the scientific perspective: novelty and obviousness, with an emphasis on the latter. The issues, decisions, and ramifications of six landmark patent litigations involving solid forms are described. These involved the following drugs: cefadroxil, terazosin hydrochloride, ranitidine hydrochloride, paroxetine hydrochloride, armodafinil, and tapentadol hydrochloride. The chapter closes with a description of the litigation on the synthetic sweetener aspartame which involved an issue of habit (shape) rather than the form (crystal structure).
1977 ◽
Vol 35
◽
pp. 24-25
1983 ◽
Vol 41
◽
pp. 518-519
1991 ◽
Vol 49
◽
pp. 562-563
1981 ◽
Vol 39
◽
pp. 354-355
1984 ◽
Vol 42
◽
pp. 428-429
1976 ◽
Vol 34
◽
pp. 400-401
1992 ◽
Vol 50
(2)
◽
pp. 1452-1453
Keyword(s):